Key Points
- Insider sale: Alane Barnes sold 150,000 shares on March 16 at an average price of $9.15 for a total of $1,372,500, cutting her stake by 27.24% to 400,703 shares (valued at about $3.67M).
- Strong recent quarter: BioCryst reported $1.12 EPS versus $0.07 expected and revenue of $163.28M (up 209% year-over-year), though analysts still project -0.36 EPS for the current fiscal year.
- Market and analyst backdrop: Shares trade near $9.16 with a $2.3B market cap, and the consensus rating is a "Moderate Buy" with an average price target of $19.64.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) insider Alane Barnes sold 150,000 shares of the company's stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $9.15, for a total value of $1,372,500.00. Following the completion of the sale, the insider owned 400,703 shares of the company's stock, valued at $3,666,432.45. This trade represents a 27.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
BioCryst Pharmaceuticals Stock Performance
Shares of BioCryst Pharmaceuticals stock opened at $9.16 on Thursday. BioCryst Pharmaceuticals, Inc. has a one year low of $6.00 and a one year high of $11.31. The company has a market cap of $2.30 billion, a price-to-earnings ratio of 7.63 and a beta of 0.74. The business's 50 day moving average price is $7.41 and its 200 day moving average price is $7.42.
BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its earnings results on Thursday, February 26th. The biotechnology company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $1.05. BioCryst Pharmaceuticals had a negative return on equity of 84.33% and a net margin of 30.16%.The company had revenue of $163.28 million during the quarter, compared to analysts' expectations of $151.32 million. During the same period in the prior year, the business earned ($0.13) EPS. The firm's quarterly revenue was up 209.1% on a year-over-year basis. On average, analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.
Hedge Funds Weigh In On BioCryst Pharmaceuticals
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Universal Beteiligungs und Servicegesellschaft mbH grew its stake in BioCryst Pharmaceuticals by 7.7% during the 2nd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 17,992 shares of the biotechnology company's stock worth $161,000 after purchasing an additional 1,288 shares in the last quarter. Royal Bank of Canada raised its holdings in BioCryst Pharmaceuticals by 2.4% in the first quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company's stock valued at $476,000 after acquiring an additional 1,458 shares in the last quarter. Cetera Investment Advisers lifted its stake in BioCryst Pharmaceuticals by 13.8% in the fourth quarter. Cetera Investment Advisers now owns 12,330 shares of the biotechnology company's stock worth $96,000 after acquiring an additional 1,494 shares during the last quarter. Captrust Financial Advisors lifted its stake in BioCryst Pharmaceuticals by 7.4% in the second quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company's stock worth $198,000 after acquiring an additional 1,527 shares during the last quarter. Finally, Main Management ETF Advisors LLC grew its holdings in BioCryst Pharmaceuticals by 1.7% during the 2nd quarter. Main Management ETF Advisors LLC now owns 112,128 shares of the biotechnology company's stock worth $1,005,000 after acquiring an additional 1,824 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company's stock.
Analyst Ratings Changes
BCRX has been the subject of several recent analyst reports. Royal Bank Of Canada cut their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an "outperform" rating for the company in a research report on Friday, January 30th. Weiss Ratings raised shares of BioCryst Pharmaceuticals from a "sell (d-)" rating to a "hold (c)" rating in a research report on Wednesday, March 4th. Evercore started coverage on shares of BioCryst Pharmaceuticals in a report on Wednesday, February 18th. They issued an "outperform" rating and a $17.00 target price for the company. Finally, HC Wainwright upped their price target on BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the stock a "buy" rating in a research note on Monday, December 15th. Ten investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat.com, BioCryst Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $19.64.
View Our Latest Stock Analysis on BioCryst Pharmaceuticals
BioCryst Pharmaceuticals Company Profile
(
Get Free Report)
BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.
The company's first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
